IFW SED

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

were the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/601171-Conf. #4940
Filing Date	June 23, 2003
First Named Inventor	Gerald R. FISCHER
Art Unit	1645
Examiner Name	N. Archie (R.A. Zeman)
Attorney Docket Number	SYNI-003CN

ENCLOSURES (Check all that apply)					
Fee Transı	mittal Form	X Drawing(s)		After Allowance Communication to TC	
Fee	Attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendment/Reply		Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After	Final	Petition to Convert to a Provisional Application		Proprietary Information	
Affid	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Add	dress	Status Letter	
Extension of Time Request		Terminal Disclaimer		X Other Enclosure(s) (please Identify below):	
Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s)		Request for Refund		Return Receipt Postcard; Response to Notice to Comply; Diskette with CRF of Substituted Sequence Listing; Paper Copy	
		CD. Number of CD(s) of Substituted Sequence Listing		of Substituted Sequence Listing; Copy of Notice to Comply; Statement Pursuant to	
				37 CFR 1.821: Appendices A-D	
Reply to Missing Parts/ Incomplete Application		Remarks	·		
	y to Missing Parts under FR 1.52 or 1.53	·			
	. <u> </u>				
	SIGNATI	JRE OF APPLICANT, ATTORNI	EY, OR	AGENT	
Firm Name	LAHIVE & COCKFIE	ELD, LLP			
Signature	Mar	9000			
Printed name	Megan E. Williams				
Date	July 24, 2006	Re	eg. No.	43,270	

Express Mail Label No. EV 553 867 405 US	Dated: July 24, 2006		



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.usoto.gov

APPLICATION NO./CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR /PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10/601,171		·	
· .			



EXAMINER

Robert A. Zeman

ART UNIT PAPER

1645

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866.

ROBERT ZEMAN
PATENT EXAMINER

Application No.: 10/601,171

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a □Sequence Listing□ as required by 37 C.F.R. 1.821(c).
	3. A copy of the Sequence Listing in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up Raw Sequence Listing.
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the Sequence Listing is not the same as the computer readable from of the □Sequence Listing□ as required by 37 C.F.R. 1.821(e).
X	7. Other: the specification contains sequences without the requisite sequence identifiers (see Figures 5 and 7 for example).
Apı	plicant Must Provide:
	An initial or <u>substitute</u> computer readable form (CRF) copy of the Sequence Listing
	An initial or <u>substitute</u> paper copy of the Sequence Listing, as well as an amendment directing its entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support Technical Assistance
	TO FUICHASE FALERIUM SORWARE/03-300-2000

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY